91 research outputs found

    Children as active researchers: A new research paradigm for the 21st century

    Get PDF
    Abstract: This paper examines the concept of research undertaken by children* and the methodological and theoretical issues this raises. It begins with a rationale for research by children and sets this within a context of participation and empowerment, acknowledging the importance of child perspective and voice and valuing the original contribution that child researchers can make to our understanding of childhood and children's lives. It traces the historical and philosophical precedents that have led to this point and explores the question of whether research by children can be accommodated within existing research parameters or whether it requires a new approach, even a new research paradigm

    NCRM Methods Review Papers, NCRM/003. Children as active researchers: a new research paradigm for the 21st century?

    Get PDF
    This paper examines the concept of research undertaken by children* and the methodological and theoretical issues this raises. It begins with a rationale for research by children and sets this within a context of participation and empowerment, acknowledging the importance of child perspective and voice and valuing the original contribution that child researchers can make to our understanding of childhood and children’s lives. It traces the historical and philosophical precedents that have led to this point and explores the question of whether research by children can be accommodated within existing research parameters or whether it requires a new approach, even a new research paradigm? The paper also addresses issues related to ethics, policy and power relations along with a discussion of the extent to which research by children can be free of adult filters and adult influence. It draws on data from a three-year action research study empowering children as active researchers and features examples of children’s original projects

    Water-soluble bis(1,10-phenanthroline) Octanedioate Cu2+ and Mn2+ Complexes with Unprecedented Nano and Picomolar in Vitro Cytotoxicity: Promising Leads for Chemotherapeutic Drug Development

    Get PDF
    Dinuclear CuII and MnII bis-phenanthroline octanedioate complexes exhibit rapid, unprecedented nano and picomolar in vitro cytotoxicity against colorectal cancer lines and are less toxic than cisplatin when examined in vivo. The complexes are potent generators of cellular reactive oxygen species, avid DNA binders and induce O2 dependent cleavage of DNA. The Cu(II) complex was found to have self-cleaving nuclease activity

    A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis:a protocol for the CLEAR clinical trial

    Get PDF
    Background: Current guidelines for the management of bronchiectasis (BE) highlight the lack of evidence to recommend mucoactive agents, such as hypertonic saline (HTS) and carbocisteine, to aid sputum removal as part of standard care. We hypothesise that mucoactive agents (HTS or carbocisteine, or a combination) are effective in reducing exacerbations over a 52-week period, compared to usual care. Methods: This is a 52-week, 2 × 2 factorial, randomized, open-label trial to determine the clinical effectiveness and cost effectiveness of HTS 6% and carbocisteine for airway clearance versus usual care-the Clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care (CLEAR) trial. Patients will be randomised to (1) standard care and twice-daily nebulised HTS (6%), (2) standard care and carbocisteine (750 mg three times per day until visit 3, reducing to 750 mg twice per day), (3) standard care and combination of twice-daily nebulised HTS and carbocisteine, or (4) standard care. The primary outcome is the mean number of exacerbations over 52 weeks. Key inclusion criteria are as follows: Adults with a diagnosis of BE on computed tomography, BE as the primary respiratory diagnosis, and two or more pulmonary exacerbations in the last year requiring antibiotics and production of daily sputum. Discussion: This trial's pragmatic research design avoids the significant costs associated with double-blind trials whilst optimising rigour in other areas of trial delivery. The CLEAR trial will provide evidence as to whether HTS, carbocisteine or both are effective and cost effective for patients with BE. Trial registration: EudraCT number: 2017-000664-14 (first entered in the database on 20 October 2017). ISRCTN.com, ISRCTN89040295. Registered on 6 July/2018. Funder: National Institute for Health Research, Health Technology Assessment Programme (15/100/01). Sponsor: Belfast Health and Social Care Trust. Ethics Reference Number: 17/NE/0339. Protocol version: V3.0 Final_14052018
    • …
    corecore